Mechanism-based inhibition of CYP3A4 and CYP2D6 by Indonesian medicinal plants

被引:33
|
作者
Subehan
Usia, Tepy
Iwata, Hiroshi
Kadota, Shigetoshi
Tezuka, Yasuhiro
机构
[1] Toyama Med & Pharmaceut Univ, Inst Nat Med, Toyama 9300194, Japan
[2] Mitsubishi Chem Safety Inst Ltd, Tokyo 3140255, Japan
[3] Toyama Med & Pharmaceut Univ, Cent COE Program 21, Toyama 9300194, Japan
关键词
Indonesian medicinal plants; mechanism-based inhibition; cytochrome P450; CYP3A4; CYP2D6;
D O I
10.1016/j.jep.2005.12.001
中图分类号
Q94 [植物学];
学科分类号
071001 ;
摘要
Thirty samples of Indonesian medicinal plants were tested for their mechanism-based inhibition on cytochrome P450 3A4 (CYP3A4) and CYP2D6 via erythromycin N-demethylation and dextromethorphan O-demethylation activities in human liver microsomes. From screening with 0 and 20 min preincubation at 0.5 mg/ml of methanol extracts, five plants (Cinnamomum burmani bark, Foeniculum vulgare seed, Strychnos ligustrina wood, Tinospora crispa stem, and Zingiber cassumunar rhizome) showed more than 30% increase of CYP3A4 inhibition, while three (Alpinia galanga rhizome, Melaleuca leucadendron leaf, and Piper nigrum fruit) showed more than 30% increase of CYP2D6 inhibition. In these eight plants, Foeniculum vulgare seed, Cinnamomum burmani bark, and Strychnos ligustrina wood showed time-dependent inhibition on CYP3A4 and Piper nigrum fruit and Melaleuca leucadendron leaf on CYP2D6. Among these, four plants other than Melaleuca leucadendron revealed NADPH-dependent inhibition. Thus, Foeniculum vulgare, Cinnamomunt burmani, and Strychnos ligustrina should contain mechanism-based inhibitors on CYP3A4 and Piper nigrum contain that on CYP2D6. (c) 2005 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:449 / 455
页数:7
相关论文
共 50 条
  • [21] The In Vitro Inhibition of Human CYP1A2, CYP2D6 and CYP3A4 by Tetrahydropalmatine, Neferine and Berberine
    Zhao, Yong
    Hellum, Bent Havard
    Liang, Aihua
    Nilsen, Odd Georg
    PHYTOTHERAPY RESEARCH, 2012, 26 (02) : 277 - 283
  • [22] Development of CYP2D6 and CYP3A4 in the first year of life
    Johnson, T. N.
    Tucker, G. T.
    Rostami-Hodjegan, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 (05) : 670 - 671
  • [23] Mechanism-based inhibition of CYP3A4 and CYP3A5 by seven inhibitors.
    Patki, KC
    von Moltke, LL
    Greenblatt, DJ
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 75 (02) : P83 - P83
  • [24] Nitidine Chloride Is a Mechanism-Based Inactivator of CYP2D6
    Mao, Xu
    Hu, Zixia
    Wang, Qian
    Zhang, Na
    Zhou, Shenzhi
    Peng, Ying
    Zheng, Jiang
    DRUG METABOLISM AND DISPOSITION, 2018, 46 (08) : 1137 - 1145
  • [25] Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates
    Filppula, A. M.
    Laitila, J.
    Neuvonen, P. J.
    Backman, J. T.
    BRITISH JOURNAL OF PHARMACOLOGY, 2012, 165 (08) : 2787 - 2798
  • [26] Mechanism-based inhibition of CYP3A4 and CYP3A5 by troleandomycin, 6′, 7 dihydroxybergamottin, diltiazem, and verapamil
    Patki, KC
    von Moltke, LL
    Greenblatt, DJ
    DRUG METABOLISM REVIEWS, 2003, 35 : 173 - 173
  • [27] Interaction of Mechanism-Based Inactivators with Modified CYP2D6
    Livezey, Mara R.
    Hicks, Michael J.
    Furge, Laura Lowe
    FASEB JOURNAL, 2013, 27
  • [28] Ecstasy (MDMA) is a mechanism-based inhibitor of CYP2D6
    Heydari, A
    Rowland, YK
    Rostami-Hodjegan, A
    Lennard, MS
    Tucker, GT
    JOURNAL OF PSYCHOPHARMACOLOGY, 2003, 17 (03) : A36 - A36
  • [29] Forecasting CYP2D6 and CYP3A4 Risk with a Global/Local Fusion Model of CYP450 Inhibition
    Ewing, Todd
    Feher, Miklos
    MOLECULAR INFORMATICS, 2010, 29 (1-2) : 127 - 141
  • [30] Mechanism-based inhibition of CYP2D6 by MDMA and its implications for pharmacokinetics and toxicity
    Yang, JS
    Jamei, M
    Heydari, A
    Yeo, KR
    de la Torre, R
    Farré, M
    Tucker, G
    Rostami-Hodjegan, A
    JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 45 (09): : 1094 - 1094